mustang
bio
licenses
technology
sirion
biotech
nasdaq
mbio
worcester
mass
martinsried
germany
globe
newswire
mustang
bio
mustang
nasdaq
mbio
sirion
biotech
gmbh
sirion
today
announced
licensing
agreement
mustang
acquired
rights
sirion
technology
development
mustang
lentiviral
gene
therapy
treatment
patients
severe
combined
immunodeficiency
xscid
also
known
bubble
boy
disease
previously
treated
hematopoietic
stem
cell
transplantation
hsct
indicated
sirion
proprietary
transduction
enhancer
lentiviral
vectors
terms
agreement
sirion
receive
undisclosed
upfront
payment
development
sales
milestones
well
royalties
future
product
sales
pleased
enter
agreement
sirion
enable
utilization
technology
development
said
manuel
litchman
president
chief
executive
officer
mustang
transduction
enhancers
added
cell
processing
lentiviral
gene
therapy
several
advantages
observed
look
forward
incorporating
plan
file
investigational
new
drug
application
ind
food
drug
administration
fda
initiate
pivotal
phase
clinical
trial
xscid
patients
age
two
received
prior
hsct
next
developed
improve
lentiviral
transduction
therapeutic
cell
types
like
hematopoietic
stem
cells
technology
enables
robust
reproducible
process
reduction
manufacturing
costs
lowering
amount
lentiviral
vectors
needed
production
cell
product
time
improving
clinical
efficacy
said
christian
thirion
chief
executive
officer
founder
sirion
delighted
mustang
chosen
technology
develop
bring
groundbreaking
xscid
therapy
lentiviral
gene
therapy
treatment
patients
severe
combined
immunodeficiency
xscid
also
known
bubble
boy
disease
previously
treated
hematopoietic
stem
cell
transplantation
hsct
indicated
lentiviral
method
employed
scientists
national
institute
allergy
infectious
diseases
niaid
part
national
institutes
health
jude
children
research
hospital
studied
niaid
since
continues
assessed
phase
clinical
trial
xscid
patients
age
two
received
prior
hsct
mustang
expects
file
ind
fda
initiate
pivotal
phase
clinical
trial
patient
population
fourth
quarter
fda
granted
orphan
drug
designation
rare
pediatric
disease
designation
treatment
xscid
previously
treated
patients
hsct
mustang
bio
mustang
bio
biopharmaceutical
company
focused
translating
today
medical
breakthroughs
cell
gene
therapies
potential
cures
hematologic
cancers
solid
tumors
rare
genetic
diseases
mustang
aims
acquire
rights
technologies
licensing
otherwise
acquiring
ownership
interest
fund
research
development
outlicense
bring
technologies
market
mustang
partnered
top
medical
institutions
advance
development
car
therapies
across
multiple
cancers
well
lentiviral
gene
therapy
xscid
mustang
registered
securities
exchange
act
amended
files
periodic
reports
securities
exchange
commission
sec
mustang
founded
fortress
biotech
nasdaq
fbio
information
visit
sirion
biotech
gmbh
sirion
biotech
founded
lead
next
generation
viral
vector
technologies
gene
cell
therapy
well
vaccine
development
sirion
offers
one
world
comprehensive
viral
vector
technology
platforms
based
viruses
expedites
gene
therapy
research
advances
drug
development
sirion
becoming
partner
choice
growing
sector
used
number
clinical
trials
early
stage
clinical
phase
late
stage
clinical
phase
trials
demonstrated
clinical
success
improving
transduction
therapeutic
vector
statements
press
release
may
contain
statements
within
meaning
section
securities
act
section
securities
exchange
act
amended
statements
include
limited
statements
relating
growth
strategy
product
development
programs
statements
historical
facts
statements
based
management
current
expectations
subject
risks
uncertainties
could
negatively
affect
business
operating
results
financial
condition
stock
value
factors
could
cause
actual
results
differ
materially
currently
anticipated
include
risks
relating
growth
strategy
ability
obtain
perform
maintain
financing
strategic
agreements
relationships
risks
relating
results
research
development
activities
risks
relating
timing
starting
completing
clinical
trials
uncertainties
relating
preclinical
clinical
testing
dependence
suppliers
ability
attract
integrate
retain
key
personnel
early
stage
products
development
need
substantial
additional
funds
government
regulation
patent
intellectual
property
matters
competition
well
risks
described
sec
filings
expressly
disclaim
obligation
undertaking
release
publicly
updates
revisions
statements
contained
herein
reflect
change
expectations
changes
events
conditions
circumstances
statement
based
except
required
law
claim
protection
safe
harbor
statements
contained
private
securities
litigation
reform
act
mustang
bio
company
contacts
jaclyn
jaffe
william
begien
mustang
bio
ir
investor
relations
contact
daniel
ferry
lifesci
advisors
llc
daniel
media
relations
contact
tony
plohoros
degrees
tplohoros
sirion
biotech
corporate
contact
dieter
lingelbach
coo
sirion
biotech
lingelbach
media
contact
usa
lisa
descenza
assistant
vice
president
integrated
communications
lavoiehealthscience
ldescenza
bd
licensing
contact
sabine
ott
senior
vp
licensing
bd
sirion
biotech
ott
